BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-23@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Tolmar Inc. — TOL2506 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Ovarian Suppression Evaluating Subc
 utaneous Leuprolide Acetate in Breast Cancer.\nSource: https://clinicaltri
 als.gov/study/NCT04906395\nhttps://catalystbrief.girapphe.com/e/23?lang=en
 \nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/23?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
